Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2020
Date of Report: July 16, 2020
Principal Executive Office: 117 Avenue de Luminy, 13009 Marseille, France
This filing serves as a cover document for the submission of a press release dated July 16, 2020 (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material changes regarding financial performance or operations are detailed in the provided text. The document solely references the existence of a press release.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are presumably contained within the referenced Exhibit 99.1 (Press Release), which is not included in the input content.
Investor Verification Checklist
- Review the full text of the Press Release dated July 16, 2020 (Exhibit 99.1) for specific operational or clinical updates.
- Verify the company's cash position and burn rate in the most recent Form 20-F or quarterly report, as this 6-K does not provide financial statements.
- Confirm the status of the company's clinical trials or regulatory milestones mentioned in the associated press release.